Basic Information
RNALocate ID: | RLID-D:11000380 |
RNA Symbol: | hsa-miR-154-5p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-154-5p |
RNA ID: | miRBase:MIMAT0000452 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
Tissue/Cell Line: | Fibroblasts|Mesenchymal stem cells |
Database: | EVmiRNA |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001838 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:11001932 | Exosome | Brain tissue | 23382797 |
RLID:11001933 | Exosome | Plasma | 23663360 |
RLID-D:11001180 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-154-5p | Oral squamous cell carcinoma | MNDR-E-MI-17418 |
MNDR | hsa-miR-154-5p | Medulloblastoma | MNDR-E-MI-17419 |
MNDR | hsa-miR-154-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-17420 |
MNDR | hsa-miR-154-5p | Ovarian clear cell carcinoma | MNDR-E-MI-17421 |
MNDR | hsa-miR-154-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-17422 |
MNDR | hsa-miR-154-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-17423 |
MNDR | hsa-miR-154-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-17424 |
MNDR | hsa-miR-154-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-17425 |
MNDR | hsa-miR-154-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-17426 |
MNDR | hsa-miR-154-5p | Her2-receptor positive breast cancer | MNDR-E-MI-17427 |
MNDR | hsa-miR-154-5p | Breast cancer luminal | MNDR-E-MI-17428 |
MNDR | hsa-miR-154-5p | Dermatomyositis | MNDR-E-MI-17429 |
MNDR | hsa-miR-154-5p | Prostate cancer | MNDR-E-MI-17430 |
MNDR | hsa-miR-154-5p | Gastric cancer | MNDR-E-MI-17431 |
MNDR | hsa-miR-154-5p | Alzheimer disease | MNDR-E-MI-17432 |
MNDR | hsa-miR-154-5p | Bladder cancer | MNDR-E-MI-17433 |
MNDR | hsa-miR-154-5p | Dysautonomia familial | MNDR-E-MI-17434 |
MNDR | hsa-miR-154-5p | Muscular dystrophy duchenne | MNDR-E-MI-17435 |
MNDR | hsa-miR-154-5p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-17436 |
MNDR | hsa-miR-154-5p | Head and neck cancer | MNDR-E-MI-17437 |
MNDR | hsa-miR-154-5p | Huntington disease | MNDR-E-MI-17438 |
MNDR | hsa-miR-154-5p | Lung cancer | MNDR-E-MI-17439 |
MNDR | hsa-miR-154-5p | Endometrial cancer | MNDR-E-MI-17440 |
MNDR | hsa-miR-154-5p | Parkinson disease | MNDR-E-MI-17441 |
MNDR | hsa-miR-154-5p | Breast cancer | MNDR-E-MI-17442 |
MNDR | hsa-miR-154-5p | Thyroid cancer | MNDR-E-MI-17443 |
MNDR | hsa-miR-154-5p | Pituitary neoplasms | MNDR-E-MI-17444 |
MNDR | hsa-miR-154-5p | Pancreatic cancer | MNDR-E-MI-17445 |
MNDR | hsa-miR-154-5p | Melanoma | MNDR-E-MI-17446 |
MNDR | hsa-miR-154-5p | Nephroblastoma | MNDR-E-MI-17447 |
MNDR | hsa-miR-154-5p | Colon cancer | MNDR-E-MI-17448 |
MNDR | hsa-miR-154-5p | Familial ovarian cancer | MNDR-E-MI-17449 |
MNDR | hsa-miR-154-5p | Prostate adenocarcinoma | MNDR-E-MI-17450 |
MNDR | hsa-miR-154-5p | Carcinoma ductal breast | MNDR-E-MI-17451 |
MNDR | hsa-miR-154-5p | Balkan nephropathy | MNDR-E-MI-17452 |
MNDR | hsa-miR-154-5p | Glioblastoma | MNDR-E-MI-17453 |
MNDR | hsa-miR-154-5p | Astrocytoma | MNDR-E-MI-17454 |
MNDR | hsa-miR-154-5p | Glioma | MNDR-E-MI-17455 |
MNDR | hsa-miR-154-5p | Nemaline myopathy | MNDR-E-MI-17456 |
MNDR | hsa-miR-154-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-17457 |
MNDR | hsa-miR-154-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-17458 |
MNDR | hsa-miR-154-5p | Meningioma | MNDR-E-MI-17459 |
MNDR | hsa-miR-154-5p | Uterine cancer | MNDR-E-MI-17460 |
MNDR | hsa-miR-154-5p | Gastric adenocarcinoma | MNDR-E-MI-17461 |
MNDR | hsa-miR-154-5p | Cervical squamous cell carcinoma | MNDR-E-MI-17462 |
MNDR | hsa-miR-154-5p | Bone-invasive pituitary adenoma | MNDR-E-MI-17463 |
MNDR | hsa-miR-154-5p | Lung adenocarcinoma | MNDR-E-MI-17464 |
MNDR | hsa-miR-154-5p | Adrenocortical carcinoma | MNDR-E-MI-17465 |
MNDR | hsa-miR-154-5p | Thyroid carcinoma | MNDR-E-MI-17466 |
MNDR | hsa-miR-154-5p | Ovarian carcinoma | MNDR-E-MI-17467 |
MNDR | hsa-miR-154-5p | Bladder urothelial carcinoma | MNDR-E-MI-17468 |
MNDR | hsa-miR-154-5p | Pancreatic adenocarcinoma | MNDR-E-MI-17469 |
MNDR | hsa-miR-154-5p | Carcinoma renal cell | MNDR-E-MI-17470 |
MNDR | hsa-miR-154-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-17471 |
MNDR | hsa-miR-154-5p | Renal clear cell carcinoma | MNDR-E-MI-17472 |
MNDR | hsa-miR-154-5p | Cholangiocarcinoma | MNDR-E-MI-17473 |
MNDR | hsa-miR-154-5p | Esophageal cancer | MNDR-E-MI-17474 |
MNDR | hsa-miR-154-5p | Synovial sarcoma | MNDR-E-MI-17475 |
MNDR | hsa-miR-154-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-17476 |
MNDR | hsa-miR-154-5p | T acute lymphoblastic leukemia | MNDR-E-MI-17477 |
MNDR | hsa-miR-154-5p | Acute t cell leukemia | MNDR-E-MI-17478 |
MNDR | hsa-miR-154-5p | Breast invasive carcinoma | MNDR-E-MI-17479 |
MNDR | hsa-miR-154-5p | Hepatocellular carcinoma | MNDR-E-MI-17480 |
MNDR | hsa-miR-154-5p | Familiar ovarian carcinoma | MNDR-E-MI-17481 |
MNDR | hsa-miR-154-5p | Neuroblastoma | MNDR-E-MI-17482 |
MNDR | hsa-miR-154-5p | Colorectal cancer | MNDR-E-MI-17483 |
MNDR | hsa-miR-154-5p | Nasopharynx carcinoma | MNDR-E-MI-17484 |
MNDR | hsa-miR-154-5p | Nasopharyngeal cancer | MNDR-E-MI-17485 |
MNDR | hsa-miR-154-5p | Prostatic neoplasms | MNDR-E-MI-17486 |
MNDR | hsa-miR-154-5p | Polymyositis | MNDR-E-MI-17487 |
MNDR | hsa-miR-154-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-17488 |
MNDR | hsa-miR-154-5p | Breast cancer her3+ negative | MNDR-E-MI-17489 |
MNDR | hsa-miR-154-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-17490 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CCND2 | Homo sapiens | RR00295032 |
TOP